|
| Scientific Program |
| |
|
| Scientific Program | Search Abstract |
| |
|
|
| Session |
| |
| Myeloma and other monoclonal gammopathies - Clinical II |
| Date: |
Saturday, 06 June 2009
|
| Time: | 18:00-19:15 |
| Room: | |
| |
| 18:00-19:15 |
|
LONGER DURATION OF TREATMENT AND MAINTENANCE OF BEST RESPONSE WITH LENALIDOMIDE DEXAMETHASONE INCREASES OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
| 0949 |
| San Miguel, Jesus,
Dimopoulos, Meletios,
Bravo, Marie-Laure,
Weber, Donna
(Salamanca, Spain) |
| |
| 18:00-19:15 |
|
CONFIRMATION OF THE UTILITY OF THE IMWG THROMBOPROPHYLAXIS STRATEGY IN MYELOMA PATIENTS RECEIVING THALIDOMIDE; EXPERIENCE OF A LARGE SINGLE CENTRE INSTITUTION
| 0950 |
| Rabin, Neil,
Fletcher, Kate Dr (P),
Aghoghovbia, Emuejevoke Dr,
Percy, Laura Dr,
Moore, Sally Dr,
Quinn, John Dr,
Cheesman, Simon Mr,
D'Sa, Shirley Dr,
Yong, Kwee Dr
(London, United Kingdom) |
| |
| 18:00-19:15 |
|
CLNICAL EFFICACY OF VEL-CTD (BORTEZOMIB, CYCLOPHOSPHAMIDE, THALIDOMIDE, AND DEXAMETHASONE) REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE II STUDY
| 0951 |
| Kim, Yeo-Kyeoung,
Ahn, Jae-Sook,
Yang, Deok-Hwan,
Sohn, Sang-Kyun,
Moon, Joon-Ho,
Kim, Hyeoung-Joon,
Shin, Ho-Jin,
Chung, Joo-Seop,
Choi, Young-Jin,
Chae, Yee-Soo,
Kim, Jong-Gwang,
Lee, Jae-Hoon,
Lee, Je-Jung,
KMMWP, .
(Gwangju, South-Korea) |
| |
| 18:00-19:15 |
|
OPTIMIZATION OF BORTEZOMIB-BASED COMBINATIVE REGIMEN IN ELDERLY RELAPSED MULTIPLE MYELOMA PATIENTS
| 0952 |
| Zahradova, Lenka,
Hajek, Roman,
Gregora, Evzen,
Schützova, Miroslava,
Adam, Zdenek,
Pour, Ludek,
Krejci, Marta,
Pavlicek, Petr,
Koza, Vladimir,
Krivanova, Andrea,
Sandecka, Viera,
Kralova, Dana
(Brno, Czech Republic) |
| |
| 18:00-19:15 |
|
EFFICACY OF PAD REGIMEN AS AN INDUCTION THERAPY BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN VAD OR CTD REFRACTORY MYELOMA
| 0953 |
| Kraj, Maria,
Warzocha, Krzysztof,
Poglód, Ryszard,
Kwasniak, Beata,
Ceglarek, Bernadeta
(Warsaw, Poland) |
| |
| 18:00-19:15 |
|
INCORPORATION OF THE BONE MARKER CARBOXY-TERMINAL TELOPEPTIDE OF TYPE-1 COLLAGEN (ICTP) INTO A COMBINED ISS-ICTP SCORE IMPROVES THE PROGNOSTIC SIGNIFICANCE OF THE ISS IN SYMPTOMATIC MULTIPLE MYELOMA
| 0954 |
| Jakob, Christian,
Sterz, J.,
Liebisch, P.,
Heider, U.,
Kaiser, M.,
Mieth, M.,
Müller, C.,
Sezer, O.
(Berlin, Germany) |
| |
| 18:00-19:15 |
|
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN PREDNISONE (MP) VERSUS MELPHALAN, PREDNISONE THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA
| 0955 |
| Sacchi, Stefano,
Marcheselli, Raffaella,
Pozzi, Samantha,
Bari, Alessia,
Ciarcia, Orsola,
Masini, Luciano,
Lazzaro, Antonio,
Morabito, Fortunato,
Fragasso, Alberto,
Di Renzo, Nicola,
Quarta, Giovanni,
Buda, Gabriele,
Musto, Pellegrino,
Vigliotti, Maria Luigia,
Pastorini, Alessandro,
Brugiatelli, Maura
(Modena, Italy) |
| |
| 18:00-19:15 |
|
SURVIVAL ANALYSIS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM REPORT FROM AN INTERNATIONAL ELECTRONIC OBSERVATIONAL STUDY OF BORTEZOMIB
| 0956 |
| Delforge, Michel,
Samblanx, Hadewijch De,
Zervas, Konstantinos,
Katodritou, Eirini,
Sargin, Deniz,
Hulin, Cyrille,
Ahlberg, Lucia,
Rubia, Javier de la,
Abdulkadyrov, Kudrat,
Ganguly, Rita,
Diels, Joris,
Dhawan, Ravinder
(Leuven, Belgium) |
| |
| 18:00-19:15 |
|
THALIDOMIDE OR BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE AS SECOND-LINE THERAPY FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA: A COMPARISON OF EFFICACY AND TOXICITY
| 0957 |
| Varettoni, Marzia
(Pavia, Italy) |
| |
| 18:00-19:15 |
|
INCREASED BONE MINERAL DENSITY IN A SUBSET OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO RECEIVED THE COMBINATION OF BORTEZOMIB, DEXAMETHASONE AND ZOLEDRONIC ACID
| 0958 |
| Terpos, Evangelos,
Christoulas, D.,
Kokkoris, P.,
Gavriatopoulou, M.,
Boutsikas, G.,
Migkou, M.,
Anargyrou, K.,
Kastritis, E.,
Tsionos, K.,
Dimopoulos, M.A.
(Athens, Greece) |
| |
| 18:00-19:15 |
|
COMBINATION OF INTERNATIONAL STAGING SYSTEM AND CYTOGENETICS CAN PREDICT POOR PROGNOSIS IN MULTIPLE MYELOMA AFTER HD-CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION
| 0959 |
| Tóthová, Elena,
Kafková, Adriana,
Štecová, Natalia,
Švorová, Erika,
Fiedlerová, Katarína,
Soska, Marek
(Košice, Slovakia) |
| |
| 18:00-19:15 |
|
THE IMPACT OF FRONTLINE TREATMENT ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA: THE SGH EXPERIENCE
| 0960 |
| Lao, Zhentang,
Wee, Wei Chieh Nelson,
Lee, Yuh Shan,
Su Su, Su.S,
Wee, Hui Chia,
Choo, An-Qi Christine,
Colin, Phipps,
Ang, Ang Ai Leen,
Yiu, Cheung Yiu,
Tan , Chen Lung Daryl,
Kam, Li Shan Grace
(Singapore, Singapore) |
| |
| 18:00-19:15 |
|
18F-FDG-PET UTILITY IN MULTIPLE MYELOMA. NEW DURIE-SALMON PLUS STAGING SYSTEM. OUR EXPERIENCE
| 0961 |
| GARCIA, ISABEL,
ENTRENA, LAURA (P),
RAMOS-FONT, CARLOS,
RODRIGUEZ-FERNANDEZ, ANTONIO
(GRANADA, Spain) |
| |
| 18:00-19:15 |
|
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN 5 PATIENTS AFFECTED BY POEMS SYNDROME
| 0962 |
| Laurenti, Luca,
De Matteis, S,
Chiusolo, P,
Piccirillo, N,
Sorà, F,
Tarnani, M,
Rossi, E,
Za, T,
Giannotta, C,
Nobile Orazio, E,
Leone, G,
Sica, S
(Rome, Italy) |
| |
| 18:00-19:15 |
|
CONTRIBUTION OF THALIDOMIDE MAINTENANCE TO LONG TERM RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
| 0963 |
| Özkurt, Zübeyde Nur,
Haznedar, Rauf,
Özkurt, Zübeyde Nur,
Yegin, Zeynep Arzu,
Aki, Sahika Zeynep,
Çeneli, Özcan,
Yagci, Münci,
Sucak, Gülsan Türköz
(Ankara, Turkey) |
| |
| 18:00-19:15 |
|
SERUM DKK1 IN SMOLDERING MULTIPLE MYELOMA
| 0964 |
| HERNANDEZ-MARTIN, JOSE,
FISAC HERRERO, ROSA MARIA,
OLIVIER CORNACCHIA, CARMEN,
TAJADA, PILAR,
MORO, MARIA JESUS,
CUELLO, REBECA,
MARTIN GARCIA-SANCHO, ALEJANDRO,
AGUILERA, CARMEN,
GARCIA-FRADE, JAVIER,
LOPEZ, LUCIA,
CASADOMARTIN, TOMAS ,
SAN MIGUEL, JESUS
(SEGOVIA, Spain) |
| |
| 18:00-19:15 |
|
ELEVETED SERUM B-LYMPHOCYTE STIMULATOR (BLYS) LEVELS IN DIAGNOSIS ARE RELATED TO DISEASE AGGRESSIVENESS AND ADVERSE SURVIVAL IN MULTIPLE MYELOMA
| 0965 |
| Maltezas, Dimitrios,
Tzenou, T.,
Papanikolaou, X.,
Koulieris, E.,
Bartzis, V.,
Gasiamis, A.,
Iliakis, T.,
Vasilakopoulos, T.P.,
Repousis, P.,
Dimou, M. ,
Georgiou, G.,
Angelopoulou, M.K.,
Kotsopoulou, M. ,
Mitsouli - Mentzikof, C.,
Panayiotidis, P.,
Pangalis, G.A.,
Kyrtsonis, M-C.
(Piraeus, Greece) |
| |
| 18:00-19:15 |
|
EPIDEMIOLOGY OF BISPHOSPHONATE USE AND JAW OSTEONECROSIS INCIDENCE IN MULTIPLE MYELOMA PATIENTS IN THE REPUBLIC OF IRELAND
| 0966 |
| McHugh, Johnny,
Kumar, R.S.,
O'Dalaigh, A.,
Breen, K.,
McCloy, M.,
Rajpal, R.,
Burke, A.,
Kelly, M.,
Desmond, R.,
O'Rafferty, C.,
Hayden, P.,
Leahy, M.
(Limerick, Ireland) |
| |
| 18:00-19:15 |
|
THE ASSOCIATION BETWEEN RESVERATROL WITH SIMVASTATIN DECREASES IGM SECRETION IN WALDENSTROM MACROGLOBULINAEMIA
| 0967 |
| Iuliano, Francesco
(Rossano, Italy) |
| |
| 18:00-19:15 |
|
THE CLINICAL SIGNIFICANCE OF TIMP-1, TIMP-2, MMP-2, MMP-9, OSTEOPROTEGERIN, SRANKL, AND ISS IN MULTIPLE MYELOMA PATIENTS
| 0968 |
| Oliveira, Luciana,
Uzielli, Juliana,
Baggio, Marcia,
Lange, Ana Paula,
Tanus-Santos, Jose Eduardo,
Rego, Eduardo
(Ribeirao Preto, Brazil) |
| |
| 18:00-19:15 |
|
EVALUATING THE POTENTIAL USE OF RISK CATEGORISATION IN THE MANAGEMENT OF MGUS
| 0969 |
| Almeshhedani, Hasham,
Salamat, Ahmed (P),
Al-Ismail, Saad
(Swansea, United Kingdom) |
| |
|